If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Aiko Nagayama is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Neoadjuvant Therapy Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences
eribulin Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Hereditary Breast and Ovarian Cancer Syndrome Medicine & Life Sciences
Antineoplastic Combined Chemotherapy Protocols Medicine & Life Sciences
olanzapine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2010 2019

  • 73 Citations
  • 4 h-Index
  • 11 Article
  • 2 Review article

Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: A multi-institutional study

Matsui, A., Murata, Y., Masuda, N., Mori, K., Takahashi, M., Yamashiro, K., Aogi, K., Maeda, S., Itou, M., Ozaki, S., Kuraoka, K., Satou, Y., Ichihara, S., Tokunaga, E., Taguchi, K., Watanabe, T., Suzuki, H., Nagayama, A. & Nishimura, R., 2019 Jan 1, In : Oncotarget. 10, 55, p. 5680-5689 10 p.

Research output: Contribution to journalArticle

Estrogen Receptors
Breast Neoplasms
Confidence Intervals

Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?

Zangardi, M. L., Spring, L. M., Nagayama, A. & Bardia, A., 2019 Feb 1, In : Expert Opinion on Investigational Drugs. 28, 2, p. 107-112 6 p.

Research output: Contribution to journalArticle

Triple Negative Breast Neoplasms
Clinical Trials, Phase I
1 Citation (Scopus)

Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis

Yokoe, T., Hayashida, T., Nagayama, A., Nakashoji, A., Maeda, H., Seki, T., Takahashi, M., Takano, T., Abe, T. & Kitagawa, Y., 2018 Jan 1, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

Hayashida, T., Jinno, H., Mori, K., Sato, H., Matsui, A., Sakurai, T., Hattori, H., Takayama, S., Wada, M., Takahashi, M., Seki, H., Seki, T., Nagayama, A., Matsumoto, A. & Kitagawa, Y., 2018 Jun 28, In : BMC Cancer. 18, 1, 701.

Research output: Contribution to journalArticle

Breast Neoplasms
Confidence Intervals
9 Citations (Scopus)

The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer

Nakashoji, A., Hayashida, T., Yokoe, T., Maeda, H., Toyota, T., Kikuchi, M., Watanuki, R., Nagayama, A., Seki, T., Takahashi, M., Abe, T. & Kitagawa, Y., 2018 Jan 1, In : Cancer Treatment Reviews. 62, p. 9-17 9 p.

Research output: Contribution to journalReview article

Neoadjuvant Therapy
Breast Neoplasms
Statistical Models
Network Meta-Analysis
human ERBB2 protein